Senicapoc
- Generic Name
- Senicapoc
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15F2NO
- CAS Number
- 289656-45-7
- Unique Ingredient Identifier
- TS6G201A6Q
- Background
Senicapoc (ICA-17043) is a novel Gardos channel blocker. It is being investigated for the treatment of sickle cell disease.
- Indication
Investigated for use/treatment in anemia (sickle cell) and asthma.
SpringWorks Therapeutics Launches with $103M to Advance Pfizer's Rare Disease Portfolio
• SpringWorks Therapeutics emerges as a Pfizer spin-off with $103 million in funding from multiple investors, including Pfizer, LifeArc, and Bain Capital, to develop four promising rare disease drug candidates.
• The company's pipeline includes nirogacestat for desmoid tumors and a MEK 1/2 inhibitor for neurofibromatosis, both advancing to phase 3 trials, along with treatments for hereditary xerocytosis and PTSD.
• Led by former Pfizer executive Lara Sullivan, SpringWorks represents a novel model for accelerating drug development by revitalizing lower-priority assets through focused development and strategic partnerships.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath